Koyfin Home > Directory > Health Care > Horizon Therapeutics > Gross Margin

Horizon Therapeutics Gross Margin Chart (HZNP)

Horizon Therapeutics annual/quarterly Gross Margin from 2010 to 2020. Gross margin is a company's total sales revenue minus its cost of goods sold (COGS), divided by total sales revenue, expressed as a percentage. The higher the percentage, the more the company retains on each dollar of sales, to service its other costs and debt obligations.
  • Horizon Therapeutics Gross Margin for the quarter ending September 09, 2020 was $76m a 3.03% increase of 2m year over year
  • Horizon Therapeutics Gross Margin for the last 12 months ending September 09, 2020 was $74m a 3.04% increase of 2m year over year
  • Horizon Therapeutics Annual Gross Margin for 2019 was $72m a 4.32% increase of 3m from 2018
  • Horizon Therapeutics Annual Gross Margin for 2018 was $69m a 6.46% increase of 4m from 2017
  • Horizon Therapeutics Annual Gross Margin for 2017 was $65m a -4.22% decrease of -3m from 2016
Other Margins & Efficiency Metrics:
  • Horizon Therapeutics EBITDA Margin for the quarter ending December 12, 2018 was $15m a 306.02% increase of 47m year over year
  • Horizon Therapeutics Return on Capital % for the quarter ending December 12, 2018 was 4.59 a 239.22% increase of 10.99 year over year
  • Horizon Therapeutics Return on Equity % for the quarter ending December 12, 2018 was 35.54 a 291.21% increase of 103.49 year over year
View Chart On Koyfin

Quarterly HZNP Gross Margin Data

09/2020$76m
06/2020$74m
03/2020$73m
12/2019$74m
09/2019$73m
06/2019$72m
03/2019$69m
12/2018$72m
09/2018$72m
06/2018$70m

Annual HZNP Gross Margin Data

2019$72m
2018$69m
2017$65m
2016$67m
2015$73m
2014$77m
2013$80m
2012$37m
2011$-5m
2010$-79m